ArticleAmerican journal of translational research2021
Clinical efficacy of self-designed Xiaoban Huoxue Prescription on chloasma derived from liver stagnation and blood stasis.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the therapeutic effect and specific mechanism of self-designed Xiaoban Huoxue Prescription on chloasma derived from liver stagnation and blood stasis.
methodsThis study retrospectively analyzed the clinical data of 94 patients with chloasma derived from liver stagnation and blood stasis. The patients were divided into a control group (treated with tranexamic acid tablets) and an experimental group (treated with self-designed Xiaoban Huoxue Prescription), with 47 cases in each group. Both groups were treated for 3 months, and the clinical efficacy was compared between the two groups.
resultsThe total response rate of the experimental group was higher than that of the control group (P<0.05). Compared with before treatment, the traditional Chinese medicine syndrome scores and Melasma area severity index scores in the two groups were lower 1, 2 and 3 months after treatment, and lower scores were seen in the experimental group than in the control group (all P<0.001); there was an opposite trend in the ITA° value (all P<0.001). Compared with before treatment, serum levels of estradiol, luteinizing hormone, follicle-stimulating hormone and tyrosinase absorbance in both groups were lower 3 months after treatment, and those in the experimental group were lower than those in the control group (all P<0.001). The experimental group had lower incidence of adverse reactions than the control group (2.13% vs. 12.77%, P<0.05). The satisfaction scores regarding pigmentation area regression, pigmentation regression and facial beauty in the experimental group were higher than those in the control group (all P<0.001).
conclusionThe self-designed Xiaoban Huoxue Prescription is safe and effective for chloasma derived from liver stagnation and blood stasis. Its mechanism may be related to the downregulation of serum sex hormone expressions and tyrosinase absorbance.
Indexed as
Identifiers
35035745PMC8748168W4206878559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.